Small-Cell Lung Cancer | Niche and Rare Pharmacor | G7 | 2015
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is particularly aggressive with a 5 year survival rate of just 5-10%. Historically, drug development in this indication has been largely unsuccessful, meaning drug treatment options are limited and the use of platinum-based therapy has remained the cornerstone of therapy for many years. SCLC treatment is yet to benefit from the emergence of targeted therapies and biomarker-associated treatments used in other oncology indications. Immune checkpoint inhibitors are now in Phase III clinical development for SCLC; these novel therapies hold promise of fulfilling the high unmet need for more effective therapies in this difficult-to-treat indication.
